Complex adaptogen drug tonizid attenuates myocardial contractility dysfunction and prevents the appearance of irreversible cardiomyocyte damage during ischemia and reperfusion in isolated heart

Yu B. Lishmanov, L. N. Maslov, A. G. Arbuzov, A. V. Krylatov, A. A. Platonov, V. N. Burkova, E. A. Kayumova

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have studied the new complex plant adaptogen preparation tonizid containing dry extracts of Aralia mandshurica, Panax ginseng, Rhodiola rosea, and Eleutherococcus senticosus. The course administration (5 days) of tonizid led to a decrease in the ratio of necrotic zone size/risk area during a 45-min local ischemia and a 2-hr reperfusion in artificially ventilated chloralose anaesthetized rats. This compound decreased the necrotic zone but did not change the size of the risk area. Tonizid also prevented an appearance of ventricular fibrillation during a 45-min coronary artery occlusion, but did not affect the incidence of ventricular arrhythmias during a brief ischemia and reperfusion. In a separate series of experiments, tonizid was administered during 5 days to rats with postinfarction cardiac sclerosis, which was formed 45 days after coronary artery occlusion. In this case, tonizid dose-dependently elevated the ventricular fibrillation threshold. The experiments in vitro were performed on a model of 35-min total ischemia and 30-min reperfusion of isolated rat heart using the Langendorff technique. The course administration of tonizid attenuated the reperfusion-induced decrease in the left ventricular pressure and the rate of contraction. However, tonizid did not prevent a reperfusion-induced reduction in the heart rate, a decrease in the rate of relaxation, and an increase in the final diastolic pressure. Tonizid decreased the creatine kinase levels in the venous effluent from isolated rat heart during reperfusion. At the same time, the plant adaptogen did not affect the incidence of ventricular arrhythmias and coronary flow. It is suggested that tonizid can be used as an adaptogen drug attenuating the contractility dysfunction and preventing an appearance of irreversible cardiomyocyte damage during ischemia and reperfusion. Tonizid exhibits cardioprotective and antifibrillatory properties during acute cardiac ischemia/reperfusion and postinfarction cardiac fibrosis.

Original languageEnglish
Pages (from-to)15-22
Number of pages8
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Volume71
Issue number3
Publication statusPublished - 2008

Fingerprint

Cardiac Myocytes
Reperfusion
Rats
Ischemia
Pharmaceutical Preparations
Plant Preparations
Chloralose
Coronary Occlusion
Ventricular Fibrillation
Creatine Kinase
Cardiac Arrhythmias
Effluents
Coronary Vessels
Aralia
Eleutherococcus
Rhodiola
Experiments
Panax
Incidence
Sclerosis

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Complex adaptogen drug tonizid attenuates myocardial contractility dysfunction and prevents the appearance of irreversible cardiomyocyte damage during ischemia and reperfusion in isolated heart. / Lishmanov, Yu B.; Maslov, L. N.; Arbuzov, A. G.; Krylatov, A. V.; Platonov, A. A.; Burkova, V. N.; Kayumova, E. A.

In: Eksperimental'naya i Klinicheskaya Farmakologiya, Vol. 71, No. 3, 2008, p. 15-22.

Research output: Contribution to journalArticle

@article{d4f9158f682c41efa94d935f867c339f,
title = "Complex adaptogen drug tonizid attenuates myocardial contractility dysfunction and prevents the appearance of irreversible cardiomyocyte damage during ischemia and reperfusion in isolated heart",
abstract = "We have studied the new complex plant adaptogen preparation tonizid containing dry extracts of Aralia mandshurica, Panax ginseng, Rhodiola rosea, and Eleutherococcus senticosus. The course administration (5 days) of tonizid led to a decrease in the ratio of necrotic zone size/risk area during a 45-min local ischemia and a 2-hr reperfusion in artificially ventilated chloralose anaesthetized rats. This compound decreased the necrotic zone but did not change the size of the risk area. Tonizid also prevented an appearance of ventricular fibrillation during a 45-min coronary artery occlusion, but did not affect the incidence of ventricular arrhythmias during a brief ischemia and reperfusion. In a separate series of experiments, tonizid was administered during 5 days to rats with postinfarction cardiac sclerosis, which was formed 45 days after coronary artery occlusion. In this case, tonizid dose-dependently elevated the ventricular fibrillation threshold. The experiments in vitro were performed on a model of 35-min total ischemia and 30-min reperfusion of isolated rat heart using the Langendorff technique. The course administration of tonizid attenuated the reperfusion-induced decrease in the left ventricular pressure and the rate of contraction. However, tonizid did not prevent a reperfusion-induced reduction in the heart rate, a decrease in the rate of relaxation, and an increase in the final diastolic pressure. Tonizid decreased the creatine kinase levels in the venous effluent from isolated rat heart during reperfusion. At the same time, the plant adaptogen did not affect the incidence of ventricular arrhythmias and coronary flow. It is suggested that tonizid can be used as an adaptogen drug attenuating the contractility dysfunction and preventing an appearance of irreversible cardiomyocyte damage during ischemia and reperfusion. Tonizid exhibits cardioprotective and antifibrillatory properties during acute cardiac ischemia/reperfusion and postinfarction cardiac fibrosis.",
author = "Lishmanov, {Yu B.} and Maslov, {L. N.} and Arbuzov, {A. G.} and Krylatov, {A. V.} and Platonov, {A. A.} and Burkova, {V. N.} and Kayumova, {E. A.}",
year = "2008",
language = "English",
volume = "71",
pages = "15--22",
journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",
issn = "0869-2092",
publisher = "Izdatelstvo Meditsina",
number = "3",

}

TY - JOUR

T1 - Complex adaptogen drug tonizid attenuates myocardial contractility dysfunction and prevents the appearance of irreversible cardiomyocyte damage during ischemia and reperfusion in isolated heart

AU - Lishmanov, Yu B.

AU - Maslov, L. N.

AU - Arbuzov, A. G.

AU - Krylatov, A. V.

AU - Platonov, A. A.

AU - Burkova, V. N.

AU - Kayumova, E. A.

PY - 2008

Y1 - 2008

N2 - We have studied the new complex plant adaptogen preparation tonizid containing dry extracts of Aralia mandshurica, Panax ginseng, Rhodiola rosea, and Eleutherococcus senticosus. The course administration (5 days) of tonizid led to a decrease in the ratio of necrotic zone size/risk area during a 45-min local ischemia and a 2-hr reperfusion in artificially ventilated chloralose anaesthetized rats. This compound decreased the necrotic zone but did not change the size of the risk area. Tonizid also prevented an appearance of ventricular fibrillation during a 45-min coronary artery occlusion, but did not affect the incidence of ventricular arrhythmias during a brief ischemia and reperfusion. In a separate series of experiments, tonizid was administered during 5 days to rats with postinfarction cardiac sclerosis, which was formed 45 days after coronary artery occlusion. In this case, tonizid dose-dependently elevated the ventricular fibrillation threshold. The experiments in vitro were performed on a model of 35-min total ischemia and 30-min reperfusion of isolated rat heart using the Langendorff technique. The course administration of tonizid attenuated the reperfusion-induced decrease in the left ventricular pressure and the rate of contraction. However, tonizid did not prevent a reperfusion-induced reduction in the heart rate, a decrease in the rate of relaxation, and an increase in the final diastolic pressure. Tonizid decreased the creatine kinase levels in the venous effluent from isolated rat heart during reperfusion. At the same time, the plant adaptogen did not affect the incidence of ventricular arrhythmias and coronary flow. It is suggested that tonizid can be used as an adaptogen drug attenuating the contractility dysfunction and preventing an appearance of irreversible cardiomyocyte damage during ischemia and reperfusion. Tonizid exhibits cardioprotective and antifibrillatory properties during acute cardiac ischemia/reperfusion and postinfarction cardiac fibrosis.

AB - We have studied the new complex plant adaptogen preparation tonizid containing dry extracts of Aralia mandshurica, Panax ginseng, Rhodiola rosea, and Eleutherococcus senticosus. The course administration (5 days) of tonizid led to a decrease in the ratio of necrotic zone size/risk area during a 45-min local ischemia and a 2-hr reperfusion in artificially ventilated chloralose anaesthetized rats. This compound decreased the necrotic zone but did not change the size of the risk area. Tonizid also prevented an appearance of ventricular fibrillation during a 45-min coronary artery occlusion, but did not affect the incidence of ventricular arrhythmias during a brief ischemia and reperfusion. In a separate series of experiments, tonizid was administered during 5 days to rats with postinfarction cardiac sclerosis, which was formed 45 days after coronary artery occlusion. In this case, tonizid dose-dependently elevated the ventricular fibrillation threshold. The experiments in vitro were performed on a model of 35-min total ischemia and 30-min reperfusion of isolated rat heart using the Langendorff technique. The course administration of tonizid attenuated the reperfusion-induced decrease in the left ventricular pressure and the rate of contraction. However, tonizid did not prevent a reperfusion-induced reduction in the heart rate, a decrease in the rate of relaxation, and an increase in the final diastolic pressure. Tonizid decreased the creatine kinase levels in the venous effluent from isolated rat heart during reperfusion. At the same time, the plant adaptogen did not affect the incidence of ventricular arrhythmias and coronary flow. It is suggested that tonizid can be used as an adaptogen drug attenuating the contractility dysfunction and preventing an appearance of irreversible cardiomyocyte damage during ischemia and reperfusion. Tonizid exhibits cardioprotective and antifibrillatory properties during acute cardiac ischemia/reperfusion and postinfarction cardiac fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=48349124649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349124649&partnerID=8YFLogxK

M3 - Article

C2 - 18652250

AN - SCOPUS:48349124649

VL - 71

SP - 15

EP - 22

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 3

ER -